BofA reiterates Buy on AstraZeneca stock, cites adjuvant trial outlook

BofA Securities reaffirmed a Buy rating and GBp165 price target on AstraZeneca, implying about 25% upside, while noting the stock trades below fair value and has a strong financial health score. The firm is cautious on the camizestrant SERENA-4 readout due in 2H 2026, but sees CAMBRIA-1 as more promising; AstraZeneca also reported a 55% reduction in progression/death risk in SERENA-6 and secured multiple FDA/European regulatory updates across Imfinzi, Datroway, and Enhertu.

Analysis

The market is still underpricing how diversified AZN’s breast-cancer franchise has become: a single binary readout is no longer the entire equity story. The more important second-order effect is that positive readthrough from SERENA-6 and recent regulatory wins reduces the financing and commercial risk embedded in the pipeline, while also giving management more leverage to sequence indications rather than rush into a suboptimal launch. That matters because the stock is likely to rerate more on durability of label expansion than on any one data point.

The near-term overhang is less clinical efficacy than timing and trial design asymmetry. The FDA delay creates a valuation pause, but it also shifts attention to CAMBRIA-1 versus SERENA-4: if monotherapy in a more endocrine-sensitive population works, it would imply the market is over-discounting SERD class utility outside combination regimens. Conversely, a negative CAMBRIA-1 would hurt sentiment less than expected if investors recognize the adjuvant opportunity can still be monetized later through broader, cleaner settings.

From a competitive standpoint, Roche and Daiichi/Sankyo are the real incremental beneficiaries if AZN stumbles, because capital would migrate toward assets with clearer regulatory visibility and simpler trial narratives. The more subtle loser is any biotech basket relying on CDK4/6 combination-heavy breast-cancer exposure, since debate around combination dilution could compress multiples across the subgroup even without direct read-through. For AZN, the setup is a classic “good company, event-driven volatility” profile: upside is more likely to be stair-stepped over months than realized in a single catalyst.

The contrarian view is that the stock’s move may already reflect too much faith in pipeline optionality and too little skepticism about execution risk across multiple launches and label expansions. If the FDA request is more than a procedural delay, the market may need to re-rate the probability of a clean 2026-27 growth bridge. In that scenario, the right trade is not to fade the franchise outright, but to express a narrower view on timing and sentiment decay.

Key Decisions for Investors

• Stay long AZN into the next 3-6 months, but size it as a core-quality/defensive growth position rather than a catalyst trade; expected reward is mid-single-digit upside from de-risking, with downside limited unless FDA issues become substantive.
• Buy AZN upside calls or call spreads into the next 1-2 quarters to capture a positive readthrough from CAMBRIA-1/CAMBRIA-2, while capping premium risk if the FDA delay drags longer than expected.
• Pair trade: long AZN / short a basket of more execution-sensitive breast-cancer peers with cleaner binary dependence on one or two readouts; this isolates pipeline durability versus single-event risk over 6-12 months.
• If trading the event, reduce AZN exposure ahead of any FDA communication and re-enter on weakness if the stock sells off on timing rather than efficacy — risk/reward favors buying procedural dips, not chasing strength.
• For portfolios overweight oncology tools/biopharma suppliers, watch for sentiment spillover into CDK4/6-adjacent names; use AZN weakness as a hedge trigger rather than a sector-wide de-risking signal.